Global Cancer Immunotherapies Market to 2024-Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient’s immune system in a general way or aiding the identification of specific antigens associated with the cancer.

The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.

The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.

Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2289762

Scope:
- Global revenue from the cancer immunotherapies market is forecast to increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a compound annual growth rate of 17.4%. What is driving this growth?
- The leading companies in terms of market share are Celgene, Merck & Co., Bristol-Myers Squibb and Roche. Which of these are forecast to experience the largest growth?
- There are some key new approvals and late-stage products set to enter the market during the forecast period. Which impact will these drugs have on the market?
- The market has been dominated by immune checkpoint inhibitors and drugs that target tumor associated antigens. To what extent will these classes of drugs and others dominate the market over the forecast period?
- There are 3,863 cancer immunotherapy products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
- Cancer immunotherapy clinical trials have an overall attrition rate of around 96%, what can companies do to maximize their chance of success?

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the cancer immunotherapy pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at current cancer immunotherapies to provide an insight into the risk associated of attempting to bring pipeline products to market.
- Predict growth in market size, with in-depth market forecasting from 2017 to 2024. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and certain patent expirations will influence market value.
- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals

Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2289762

Key Points from TOC:
2 Introduction 12
3 Key Marketed Products 49
3.1 Overview 49
3.2 Revlimid (lenalidomide) - Celgene 50
3.3 Opdivo (nivolumab) - Ono Pharma/Bristol-Myers Squibb 53
3.4 Keytruda (pembrolizumab) - Merck & Co. 55
3.5 Tecentriq (atezolizumab) - Roche 57
3.6 Darzalex (daratumumab) - Johnson & Johnson 59
3.7 Imfinzi (durvalumab) - AstraZeneca/Celgene 60
3.8 Gardasil/Gardasil 9 (human papillomavirus vaccine) - Merck & Co. 62
3.9 Pomalyst/Imnovid (pomalidomide) - Celgene 65
3.10 Yescarta (axicabtagene ciloleucel) - Gilead Sciences 66
3.11 Gazyva (obinutuzumab) - Roche 68
3.12 Yervoy (ipilimumab) - Bristol-Myers Squibb 69
3.13 Rituxan (rituximab) - Roche/Biogen 71
3.14 Kymriah (tisagenlecleucel) - Novartis 73
4 Pipeline Landscape Assessment 76
4.1 Overview 76
4.2 Pipeline Development Landscape 76
4.3 Molecular Targets in the Pipeline 79
4.4 Clinical Trials Landscape 82
4.4.1 Clinical Trial Failure Rates 83
4.4.2 Clinical Trial Duration 87
4.4.3 Clinical Trial Size 91
4.4.4 Cumulative Clinical Trial Size 94
4.5 Late-Stage Drugs of the Developmental Pipeline 99
4.5.1 Lisocabtagene maraleucel - Juno Therapeutics/Celgene 99
4.5.2 Durvalumab plus Tremelimumab - AstraZeneca 100
4.5.3 Tremelimumab - AstraZeneca 101
4.5.4 Cemiplimab - Regeneron/Sanofi 103
4.5.5 Epacadostat - Incyte Corp 104
4.5.6 Axalimogene filolisbac - Advaxis 106
5 Multi-scenario Market Forecast to 2024 108
6 Company Analysis and Positioning 119
6.1 Revenue and Market Share Analysis by Company 120
6.1.1 Celgene - Revlimid to Maintain Celgene’s Position as Market Leader 124
6.1.2 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth 126
6.1.3 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies 127
6.1.4 Roche - Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan 127
6.1.5 AstraZeneca - Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence 128
6.1.6 Johnson & Johnson - Darzalex Key to Strong Growth 130
6.1.7 Novartis - Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue 131
6.1.8 AbbVie - Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024 132
6.1.9 Gilead Sciences - Growth Driven by CAR-T Therapy Yescarta 133
6.1.10 Amgen - Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters 134
6.2 Market and Pipeline Company Landscape 134
7 Strategic Consolidations 138
8 Appendix 164

Get More Information about the Report@ http://www.orbisresearch.com/reports/index/global-cancer-immunotherapies-market-to-2024-increased-uptake-of-immune-checkpoint-inhibitors-driving-growth-supported-by-a-large-robust-pipeline

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email id: sales@orbisresearch.com

This release was published on openPR.